Exenatide
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients
AstraZeneca · Phase 3 · Terminated · Enrollment 13
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Dapagliflozin plus Exenatide | n/r | n/r | n/r | n/r |
| Placebo plus Placebo | n/r | n/r | n/r | n/r |
| Placebo plus Exenatide | n/r | n/r | n/r | n/r |
Not shown
- Dapagliflozin plus Exenatide: endpoint not reported
- Placebo plus Placebo: endpoint not reported
- Placebo plus Exenatide: endpoint not reported